Nektar Therapeutics (NKTR) Misses Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $64.85 -2.76%
EPS Growth %: +26.6%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +26.6%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.57), $0.03 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $45.92 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
- Goldman Sachs plans 11% dividend increase after Fed stress test
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
